The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...

GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children ...

The U.S. Food and Drug Administration has granted approval to a new antibiotic to treat urinary tract infections in women and ...

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved Blujepa for the treatment of female adults and pediatric ...

London: GSK plc has announced that the Company has received US Food and Drug Administration (FDA) approval for Blujepa ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections (UTIs), the first such drug approved in decades and the first in a new class of medications.